Related Experiment Video
Updated: Jun 24, 2026

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library
Published on: April 6, 2012
c-Src promotes tumor progression through downregulation of microRNA-129-1-3p
Daisuke Okuzaki1, Tomoe Yamauchi2, Fumie Mitani2
1Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
Abstract:
MicroRNAs (miRNAs) fine-tune cellular signaling by regulating expression of signaling proteins, and aberrant expression of miRNAs is observed in many cancers. The tyrosine kinase c-Src is upregulated in various human cancers, but the molecular mechanisms underlying c-Src-mediated tumor progression remain unclear. In previous investigations of miRNA-mediated control of c-Src-related oncogenic pathways, we identified miRNAs that were downregulated in association with c-Src transformation and uncovered the signaling networks by predicting their target genes, which might act cooperatively to control tumor progression. Here, to further elucidate the process of cell transformation driven by c-Src, we analyzed the expression profiles of miRNAs in a doxycycline-inducible Src expression system. We found that miRNA (miR)-129-1-3p was downregulated in the early phase of c-Src-induced cell transformation, and that reexpression of miR-129-1-3p disrupted c-Src-induced cell transformation. In addition, miR-129-1-3p downregulation was tightly associated with tumor progression in human colon cancer cells/tissues. Expression of miR-129-1-3p in human colon cancer cells caused morphological changes and suppressed tumor growth, cell adhesion, and invasion. We also identified c-Src and its critical substrate Fer, and c-Yes, a member of the Src family of kinases, as novel targets of miR-129-1-3p. Furthermore, we found that miR-129-1-3p-mediated regulation of c-Src/Fer and c-Yes is important for controlling cell adhesion and invasion. Downregulation of miR-129-1-3p by early activation of c-Src increases expression of these target genes and synergistically promotes c-Src-related oncogenic signaling. Thus, c-Src-miR-129-1-3p circuits serve as critical triggers for tumor progression in many human cancers that harbor upregulation of c-Src.
Insights
MicroRNA-129-1-3p downregulation promotes cancer by enabling tyrosine kinase c-Src signaling. Restoring this microRNA inhibits tumor growth, adhesion, and invasion in colon cancer.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- MicroRNAs (miRNAs) regulate cellular signaling and are often dysregulated in cancer.
- The tyrosine kinase c-Src is frequently upregulated in cancers, contributing to tumor progression through unclear mechanisms.
Purpose of the Study:
- To investigate the role of miRNAs in c-Src-induced cell transformation.
- To identify specific miRNAs and their targets involved in c-Src-mediated oncogenesis.
Main Methods:
- Analysis of miRNA expression profiles in a doxycycline-inducible Src system.
- Functional assays assessing the impact of miR-129-1-3p reexpression on cell transformation, growth, adhesion, and invasion.
- Identification of direct miRNA targets using molecular biology techniques.
Main Results:
- miR-129-1-3p was found to be downregulated early in c-Src-induced cell transformation.
- Reexpression of miR-129-1-3p suppressed c-Src-driven cell transformation, tumor growth, adhesion, and invasion in colon cancer cells.
- c-Src, Fer, and c-Yes were identified as direct targets of miR-129-1-3p.
- Downregulation of miR-129-1-3p by c-Src activation leads to increased expression of its targets, promoting oncogenic signaling.
Conclusions:
- miR-129-1-3p acts as a tumor suppressor by targeting c-Src, Fer, and c-Yes.
- The c-Src-miR-129-1-3p regulatory circuit is a critical driver of tumor progression in cancers with elevated c-Src.
- Targeting this circuit may offer therapeutic strategies for c-Src-driven cancers.
Related Concept Videos
MicroRNAs
MicroRNAs
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
MicroRNAs
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

